Halozyme Therapeutics (HALO)
Market Price (9/21/2026): $112.77 | Market Cap: $13.2 BilSector: Health Care | Industry: Biotechnology
Halozyme Therapeutics (HALO)
Market Price (9/21/2026): $112.77Market Cap: $13.2 BilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 41% Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 56% Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 49%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 31% Low stock price volatilityVol 12M is 37% Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more. | Trading close to highsDist 52W High is 0.0%, Dist 3Y High is 0.0% Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 13% | Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 22x, P/EPrice/Earnings or Price/(Net Income) is 32x Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 57% Key risksHALO key risks include [1] the 2027 patent expiration of its core ENHANZE technology, Show more. |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 41% |
| Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 56% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 49%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 31% |
| Low stock price volatilityVol 12M is 37% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more. |
| Trading close to highsDist 52W High is 0.0%, Dist 3Y High is 0.0% |
| Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 13% |
| Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 22x, P/EPrice/Earnings or Price/(Net Income) is 32x |
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 57% |
| Key risksHALO key risks include [1] the 2027 patent expiration of its core ENHANZE technology, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Halozyme Therapeutics (HALO) stock has gained about 70% since 5/31/2026 because of the following key factors:
1. Exceptional Q2 fiscal year 2026 Financial Performance and Upgraded Outlook.
Halozyme Therapeutics reported robust Q2 fiscal year 2026 results on August 6, 2026, with earnings per share (EPS) of $2.28, significantly exceeding analysts' expectations of $1.80 by 26.67%. Quarterly revenue surged by 47.7% year-over-year to $481 million, surpassing the consensus estimate of $402.28 million. This strong financial performance was driven by a 50% year-over-year increase in royalty revenue to $307.7 million and a 59% year-over-year rise in net product sales to $129.6 million in the quarter. Following these results, the company raised its full-year fiscal year 2026 guidance, projecting total revenue between $1.835 billion and $1.910 billion (representing 31% to 37% growth) and non-GAAP diluted EPS of $8.65 to $9.00 (a 108% to 117% growth).
2. Strategic Expansion of Drug Delivery Platforms Through Key Partnerships.
Halozyme successfully broadened the reach of its proprietary ENHANZE® and Hypercon™ drug delivery technologies by signing five new collaboration agreements year-to-date in fiscal year 2026, exceeding its annual goal of three new deals. Key agreements included a global collaboration and license agreement with GSK in May fiscal year 2026 to develop subcutaneous formulations of multiple oncology targets, notably marking the first application of ENHANZE® with antibody-drug conjugates (ADCs). Additionally, in July fiscal year 2026, Halozyme entered into a global collaboration and license agreement with Incyte to evaluate subcutaneous formulations of INCA033989 for myeloproliferative neoplasms. These partnerships, along with earlier 2026 agreements with Vertex Pharmaceuticals and Oruka Therapeutics for Hypercon™ technology, involve upfront payments, potential future milestone payments, and royalties, signaling strong industry demand and substantial long-term revenue potential.
Show more
Halozyme Therapeutics (HALO) stock has gained about 70% since 5/31/2026 because of the following key factors:
1. Exceptional Q2 fiscal year 2026 Financial Performance and Upgraded Outlook.
Halozyme Therapeutics reported robust Q2 fiscal year 2026 results on August 6, 2026, with earnings per share (EPS) of $2.28, significantly exceeding analysts' expectations of $1.80 by 26.67%. Quarterly revenue surged by 47.7% year-over-year to $481 million, surpassing the consensus estimate of $402.28 million. This strong financial performance was driven by a 50% year-over-year increase in royalty revenue to $307.7 million and a 59% year-over-year rise in net product sales to $129.6 million in the quarter. Following these results, the company raised its full-year fiscal year 2026 guidance, projecting total revenue between $1.835 billion and $1.910 billion (representing 31% to 37% growth) and non-GAAP diluted EPS of $8.65 to $9.00 (a 108% to 117% growth).
2. Strategic Expansion of Drug Delivery Platforms Through Key Partnerships.
Halozyme successfully broadened the reach of its proprietary ENHANZE® and Hypercon™ drug delivery technologies by signing five new collaboration agreements year-to-date in fiscal year 2026, exceeding its annual goal of three new deals. Key agreements included a global collaboration and license agreement with GSK in May fiscal year 2026 to develop subcutaneous formulations of multiple oncology targets, notably marking the first application of ENHANZE® with antibody-drug conjugates (ADCs). Additionally, in July fiscal year 2026, Halozyme entered into a global collaboration and license agreement with Incyte to evaluate subcutaneous formulations of INCA033989 for myeloproliferative neoplasms. These partnerships, along with earlier 2026 agreements with Vertex Pharmaceuticals and Oruka Therapeutics for Hypercon™ technology, involve upfront payments, potential future milestone payments, and royalties, signaling strong industry demand and substantial long-term revenue potential.
3. Robust Capital Management Through Share Repurchases and Debt Offering.
The company demonstrated confidence in its valuation and commitment to shareholder returns by initiating a new $1 billion share repurchase program in May fiscal year 2026, with a commitment to repurchase at least $400 million in fiscal year 2026. During Q2 fiscal year 2026, Halozyme repurchased 4.8 million shares for $332.8 million. Furthermore, in September fiscal year 2026, Halozyme successfully priced an upsized private offering of $1.3 billion in 1.50% convertible senior notes due 2033, an increase from the initially announced $1.05 billion. The conversion price of approximately $139.84 per share represented a 27.5% premium over the closing price of $109.68 on September 17, 2026, indicating strong investor demand and providing substantial capital for general corporate purposes, including the repurchase of existing convertible notes.
Show less
Stock Movement Drivers
Fundamental Drivers
The 69.0% change in HALO stock from 5/31/2026 to 9/20/2026 was primarily driven by a 41.5% change in the company's P/E Multiple.| (LTM values as of) | 5312026 | 9202026 | Change |
|---|---|---|---|
| Stock Price ($) | 66.54 | 112.45 | 69.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,508 | 1,664 | 10.3% |
| Net Income Margin (%) | 23.1% | 24.9% | 7.5% |
| P/E Multiple | 22.5 | 31.9 | 41.5% |
| Shares Outstanding (Mil) | 118 | 117 | 0.7% |
| Cumulative Contribution | 69.0% |
Market Drivers
5/31/2026 to 9/20/2026| Return | Correlation | |
|---|---|---|
| HALO | 69.0% | |
| Market (SPY) | 0.9% | 9.7% |
| Sector (XLV) | 12.7% | 39.8% |
Fundamental Drivers
The 61.7% change in HALO stock from 2/28/2026 to 9/20/2026 was primarily driven by a 23.5% change in the company's P/E Multiple.| (LTM values as of) | 2282026 | 9202026 | Change |
|---|---|---|---|
| Stock Price ($) | 69.53 | 112.45 | 61.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,397 | 1,664 | 19.1% |
| Net Income Margin (%) | 22.7% | 24.9% | 9.6% |
| P/E Multiple | 25.8 | 31.9 | 23.5% |
| Shares Outstanding (Mil) | 118 | 117 | 0.3% |
| Cumulative Contribution | 61.7% |
Market Drivers
2/28/2026 to 9/20/2026| Return | Correlation | |
|---|---|---|
| HALO | 61.7% | |
| Market (SPY) | 11.6% | 20.8% |
| Sector (XLV) | 5.5% | 47.3% |
Fundamental Drivers
The 53.7% change in HALO stock from 8/31/2025 to 9/20/2026 was primarily driven by a 100.2% change in the company's P/E Multiple.| (LTM values as of) | 8312025 | 9202026 | Change |
|---|---|---|---|
| Stock Price ($) | 73.15 | 112.45 | 53.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,179 | 1,664 | 41.2% |
| Net Income Margin (%) | 47.3% | 24.9% | -47.4% |
| P/E Multiple | 15.9 | 31.9 | 100.2% |
| Shares Outstanding (Mil) | 121 | 117 | 3.5% |
| Cumulative Contribution | 53.7% |
Market Drivers
8/31/2025 to 9/20/2026| Return | Correlation | |
|---|---|---|
| HALO | 53.7% | |
| Market (SPY) | 19.4% | 19.4% |
| Sector (XLV) | 24.1% | 42.0% |
Fundamental Drivers
The 164.2% change in HALO stock from 8/31/2023 to 9/20/2026 was primarily driven by a 115.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 8312023 | 9202026 | Change |
|---|---|---|---|
| Stock Price ($) | 42.56 | 112.45 | 164.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 774 | 1,664 | 115.0% |
| Net Income Margin (%) | 30.2% | 24.9% | -17.7% |
| P/E Multiple | 24.0 | 31.9 | 32.9% |
| Shares Outstanding (Mil) | 132 | 117 | 12.3% |
| Cumulative Contribution | 164.2% |
Market Drivers
8/31/2023 to 9/20/2026| Return | Correlation | |
|---|---|---|
| HALO | 164.2% | |
| Market (SPY) | 75.6% | 25.3% |
| Sector (XLV) | 32.3% | 42.1% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| HALO Return | -6% | 42% | -35% | 29% | 41% | 63% | 157% |
| Peers Return | 37% | -2% | 25% | -7% | -4% | 16% | 72% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 12% | 103% |
Monthly Win Rates [3] | |||||||
| HALO Win Rate | 42% | 58% | 33% | 50% | 58% | 67% | |
| Peers Win Rate | 67% | 48% | 50% | 45% | 50% | 58% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 44% | |
Max Drawdowns [4] | |||||||
| HALO Max Drawdown | -38% | -26% | -47% | -34% | -32% | -24% | |
| Peers Max Drawdown | -15% | -32% | -28% | -25% | -33% | -23% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: ABBV, PFE, BDX, WST, AMPH.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 9/18/2026 (YTD)
How Low Can It Go
| Event | HALO | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -17.1% | -18.8% |
| % Gain to Breakeven | 20.6% | 23.1% |
| Time to Breakeven | 63 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -22.2% | -9.5% |
| % Gain to Breakeven | 28.5% | 10.5% |
| Time to Breakeven | 197 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -38.3% | -6.7% |
| % Gain to Breakeven | 62.2% | 7.1% |
| Time to Breakeven | 395 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -22.1% | -24.5% |
| % Gain to Breakeven | 28.4% | 32.4% |
| Time to Breakeven | 64 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -34.3% | -33.7% |
| % Gain to Breakeven | 52.3% | 50.9% |
| Time to Breakeven | 35 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -28.6% | -19.2% |
| % Gain to Breakeven | 40.0% | 23.8% |
| Time to Breakeven | 326 days | 105 days |
In The Past
Halozyme Therapeutics's stock fell -17.1% during the 2025 US Tariff Shock. Such a loss loss requires a 20.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | HALO | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -22.2% | -9.5% |
| % Gain to Breakeven | 28.5% | 10.5% |
| Time to Breakeven | 197 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -38.3% | -6.7% |
| % Gain to Breakeven | 62.2% | 7.1% |
| Time to Breakeven | 395 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -22.1% | -24.5% |
| % Gain to Breakeven | 28.4% | 32.4% |
| Time to Breakeven | 64 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -34.3% | -33.7% |
| % Gain to Breakeven | 52.3% | 50.9% |
| Time to Breakeven | 35 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -28.6% | -19.2% |
| % Gain to Breakeven | 40.0% | 23.8% |
| Time to Breakeven | 326 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -33.0% | -3.7% |
| % Gain to Breakeven | 49.2% | 3.9% |
| Time to Breakeven | 9 days | 6 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -63.7% | -12.2% |
| % Gain to Breakeven | 175.7% | 13.9% |
| Time to Breakeven | 672 days | 62 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -24.5% | -6.8% |
| % Gain to Breakeven | 32.5% | 7.3% |
| Time to Breakeven | 23 days | 15 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -21.1% | -17.9% |
| % Gain to Breakeven | 26.7% | 21.8% |
| Time to Breakeven | 71 days | 123 days |
| 2010 Eurozone Sovereign Debt Crisis / Flash Crash | ||
| % Loss | -27.4% | -15.4% |
| % Gain to Breakeven | 37.7% | 18.2% |
| Time to Breakeven | 507 days | 125 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -62.1% | -53.4% |
| % Gain to Breakeven | 163.5% | 114.4% |
| Time to Breakeven | 180 days | 1085 days |
| Summer 2007 Credit Crunch | ||
| % Loss | -22.5% | -8.6% |
| % Gain to Breakeven | 29.0% | 9.5% |
| Time to Breakeven | 33 days | 47 days |
In The Past
Halozyme Therapeutics's stock fell -17.1% during the 2025 US Tariff Shock. Such a loss loss requires a 20.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Halozyme Therapeutics (HALO)
Halozyme Therapeutics, Inc. is a biopharma technology platform company specializing in enhancing the delivery of injectable drugs. Its core innovation is the proprietary ENHANZE drug delivery technology, which utilizes a recombinant human hyaluronidase enzyme (rHuPH20). This technology allows for the subcutaneous (under the skin) administration of various therapeutic molecules, including biologics like monoclonal antibodies, small molecules, and fluids, making injections more convenient and efficient for patients and healthcare providers.
While Halozyme offers Hylenex recombinant, a direct product of its rHuPH20 enzyme for facilitating subcutaneous fluid administration and drug dispersion, its primary business model revolves around licensing its ENHANZE technology. This technology is incorporated into numerous partner products, significantly expanding their market reach and patient convenience. Key examples include therapies such as Perjeta, RITUXAN HYCELA, MabThera SC, HYQVIA, Tecentriq, OCREVUS, DARZALEX, and nivolumab, used across a wide spectrum of diseases.
Halozyme's primary customers are leading global pharmaceutical and biotechnology companies, which license and integrate the ENHANZE technology into their own drug pipelines. These strategic collaborations include major players like F. Hoffmann-La Roche, Pfizer, Janssen Biotech, AbbVie, Eli Lilly and Company, and Bristol-Myers Squibb, among others. Through these partnerships, Halozyme's technology ultimately benefits patients worldwide suffering from conditions such as various cancers (e.g., non-Hodgkin lymphoma, CLL, non-small cell lung cancer, multiple myeloma), immunodeficiency disorders, multiple sclerosis, autoimmune diseases, and HIV.
AI Analysis | Feedback
Here are 1-3 brief analogies for Halozyme Therapeutics (HALO):
- The "Intel Inside" for injectable drugs.
- Dolby Laboratories for drug administration.
AI Analysis | Feedback
- ENHANZE Drug Delivery Technology: A patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, small molecules, and fluids.
- Hylenex Recombinant: A formulation of rHuPH20 used to facilitate subcutaneous fluid administration and enhance the dispersion and absorption of other injected drugs.
- Perjeta (subcutaneous formulation): A therapeutic biologic delivered subcutaneously for cancer treatment, enabled by ENHANZE technology through a partnership.
- RITUXAN HYCELA / MabThera SC: Subcutaneous formulations for treating non-Hodgkin lymphoma and chronic lymphocytic leukemia, leveraging ENHANZE technology.
- HYQVIA: A subcutaneous immunoglobulin treatment for immunodeficiency disorders, enhanced by ENHANZE for improved delivery.
- DARZALEX (subcutaneous formulation): An injectable biologic in development for multiple myeloma and amyloidosis, utilizing ENHANZE for subcutaneous administration.
AI Analysis | Feedback
Halozyme Therapeutics (HALO) is a biopharma technology platform company that primarily sells its ENHANZE drug delivery technology through collaborations and licensing agreements with other pharmaceutical and biotech companies. Its major customers are these partner companies:
- Roche (OTCQX: RHHBY)
- Takeda Pharmaceutical Company Limited (NYSE: TAK)
- Pfizer Inc. (NYSE: PFE)
- Johnson & Johnson (NYSE: JNJ)
- AbbVie, Inc. (NYSE: ABBV)
- Eli Lilly and Company (NYSE: LLY)
- Bristol-Myers Squibb Company (NYSE: BMY)
- AstraZeneca (NASDAQ: AZN)
- Argenx SE (NASDAQ: ARGX)
- Amgen (NASDAQ: AMGN)
- GSK (NYSE: GSK)
AI Analysis | Feedback
AI Analysis | Feedback
Helen Torley, President and Chief Executive Officer
Dr. Helen Torley has served as President and Chief Executive Officer of Halozyme Therapeutics since January 2014. She is also a member of the company's Board of Directors. Prior to joining Halozyme, Dr. Torley was Executive Vice President and Chief Commercial Officer at Onyx Pharmaceuticals, a subsidiary of Amgen, where she was responsible for the successful launch of Kyprolis in the U.S. and oversaw the development and commercial collaboration with Bayer on Nexavar and Stivarga. She spent 14 years in various management positions at Amgen in the Nephrology and Bone Health Business Units. Before Amgen, she held senior positions at Bristol-Myers Squibb, including Regional Vice President of Cardiovascular and Metabolic Sales and Head of Cardiovascular Global Marketing. Dr. Torley began her industry career at Sandoz/Novartis, ultimately serving as Vice President of Medical Affairs. She has led multiple successful product launches throughout her career, including Kyprolis, Prolia, Sensipar, and Miacalcin. Dr. Torley initially practiced as a physician specializing in rheumatology after graduating from medical school.
David Ramsay, Interim Chief Financial Officer
David Ramsay has been appointed Interim Chief Financial Officer of Halozyme Therapeutics, effective March 23, 2026. He will oversee all financial operations while the company conducts a search for a permanent CFO. Mr. Ramsay brings over 30 years of strategic financial leadership experience across the biotechnology and life sciences sectors. He previously served as Halozyme's Chief Financial Officer from 2003 to 2009 and again from 2013 to 2015, during which time he played a key role in the company's evolution from a private enterprise to a billion-dollar public biopharmaceutical company. Before his current interim appointment, Mr. Ramsay was Senior Vice President and Chief Financial Officer of Bonti, Inc. until its sale to Allergan plc in October 2018.
Cortney Caudill, Senior Vice President and Chief Operating Officer
Cortney Caudill serves as the Senior Vice President and Chief Operating Officer at Halozyme Therapeutics. Further detailed background information beyond her title at Halozyme was not immediately available in the search results.
Mark Snyder, Senior Vice President, General Counsel, Chief Compliance Officer and Secretary
Mark Snyder holds the positions of Senior Vice President, General Counsel, Chief Compliance Officer, and Secretary at Halozyme Therapeutics. Further detailed background information beyond his titles at Halozyme was not immediately available in the search results.
Dimitrios Chondros, Senior Vice President, Chief Medical Officer
Dimitrios Chondros serves as Senior Vice President and Chief Medical Officer at Halozyme Therapeutics. Further detailed background information beyond his titles at Halozyme was not immediately available in the search results.
AI Analysis | Feedback
The key risks to Halozyme Therapeutics (HALO) include:
- Dependency on partner success and collaborations: Halozyme's business model heavily relies on its ENHANZE drug delivery technology being licensed to and successfully utilized by major pharmaceutical companies for their injectable biologics. The commercial success, regulatory approval, and continued development of partner drugs (such as Perjeta, RITUXAN HYCELA, Tecentriq, OCREVUS, and DARZALEX) are critical revenue drivers for Halozyme through royalties and milestones. Any clinical trial failures, regulatory hurdles, or lower-than-expected commercial performance of these partner products, or a decision by partners not to renew or expand existing collaborations, could significantly impact Halozyme's revenue and financial performance.
- Intellectual property protection and patent expiration: The core of Halozyme's technology platform is its patented recombinant human hyaluronidase enzyme (rHuPH20). The ability to maintain and enforce these patents, as well as the eventual expiration of key patents, poses a significant risk. Loss of patent protection could allow competitors to develop and commercialize similar technologies without licensing, thereby eroding Halozyme's competitive advantage and revenue streams.
- Competition from alternative drug delivery technologies: While ENHANZE offers a unique solution for subcutaneous drug delivery, the pharmaceutical landscape is dynamic. The emergence of new or improved alternative drug delivery methods, or even entirely new therapeutic modalities that reduce or eliminate the need for enhanced subcutaneous delivery, could diminish the demand for Halozyme's technology platform, affecting its market position and growth prospects.
AI Analysis | Feedback
AI Analysis | Feedback
Halozyme Therapeutics' core offerings, including its ENHANZE drug delivery technology and Hylenex recombinant product, operate within significant global addressable markets.
The global hyaluronidase market, which includes recombinant human hyaluronidase (rHuPH20) like Halozyme's ENHANZE enzyme and Hylenex, was valued at over USD 1.8 billion in 2025 and is projected to reach USD 6.4 billion by the end of 2035, growing at a Compound Annual Growth Rate (CAGR) of 15.2% from 2026 to 2035. In 2026, this market is assessed at USD 2 billion.
The broader global subcutaneous drug delivery market, which Halozyme's ENHANZE technology facilitates by enabling the subcutaneous administration of biologics, is projected to grow from USD 34.9 billion in 2025 to USD 66.7 billion by 2035, at a CAGR of 6.7% over the forecast period.
AI Analysis | Feedback
- Continued Growth in ENHANZE® Royalty Revenue: Halozyme anticipates sustained and significant growth in royalty revenue from its ENHANZE® drug delivery technology, particularly from blockbuster partner products. Key contributors to this growth include DARZALEX SC (Janssen), Phesgo (Roche), and VYVGART Hytrulo (argenx), which have demonstrated strong sales uptake across various geographies. The company expects royalty revenue to exceed $1 billion in 2026, representing a 30% to 35% growth over 2025.
- Expansion of the ENHANZE® Platform through New Collaborations: Halozyme is actively expanding its ENHANZE® platform by securing new collaboration and licensing agreements. In 2025, the company added three new collaboration and licensing agreements and gained one new target nomination from Roche. Halozyme plans to sign at least three new licensing agreements in 2026, including new ENHANZE collaborations, which will broaden the pipeline of ENHANZE-enabled products and future revenue streams.
- Regulatory Approvals and Geographic Expansion of Partner Products: New regulatory approvals and expanded indications for ENHANZE®-enabled products in various markets are expected to fuel revenue growth. Recent examples include Janssen's global approvals for Rybrevant SC in the U.S., China, and Japan, and new indication approvals for DARZALEX Faspro. Furthermore, a new European patent for ENHANZE®, valid until 2029 for DARZALEX SC, helps secure ongoing royalty rates in the region.
- Integration and Leverage of Acquired Drug Delivery Technologies: The acquisitions of Elektrofi's Hypercon™ technology and Surf Bio's hyperconcentration technology in 2025 are strategic moves to diversify and extend Halozyme's drug delivery portfolio. These technologies are anticipated to meaningfully expand the company's long-term royalty opportunity into the mid-2040s. Halozyme expects to sign one to two new Hypercon collaborations in 2026, further leveraging these new assets.
- Growth in XYOSTED® Product Sales: While royalty revenue remains the primary driver, Halozyme also anticipates continued growth in product sales from its proprietary product, XYOSTED®. This contributes to the company's overall total revenue growth.
AI Analysis | Feedback
Share Repurchases
- Halozyme Therapeutics completed repurchases of 11,177,781 shares for a total of $592.37 million under a buyback plan announced on February 20, 2024.
- In December 2021, Halozyme's Board of Directors authorized a new share repurchase program for up to $750 million of its outstanding common stock over three years.
- Under this program, Halozyme entered into a new $250 million accelerated share repurchase (ASR) program in January 2025, with another $250 million share repurchase announced in May 2025.
Share Issuance
- Halozyme Therapeutics has primarily been repurchasing shares rather than issuing them, as evidenced by a net issuance of common stock amounting to -$571.1 million based on the financial report for September 30, 2025.
- The company's shares outstanding have consistently declined year-over-year, including a 6% decline for the quarter ending September 30, 2025, and a 3.56% decline in 2024.
Inbound Investments
- No information regarding large, one-off inbound investments by third-parties, such as strategic equity investments or private equity firm stakes in Halozyme Therapeutics, was found over the last 3-5 years. Halozyme's business model includes upfront licensing fees, milestone payments, and royalties from collaborative agreements, which are part of its operating revenue.
Outbound Investments
- While Halozyme's capital allocation strategy includes potential mergers and acquisitions (M&A) to expand its platform, no significant outbound investments or acquisitions by Halozyme Therapeutics have been reported in the last 3-5 years.
Capital Expenditures
- Halozyme Therapeutics's Capital Expenditures amounted to -$294.7 million for its fiscal year ending December 31, 2025.
- Capital expenditures in the most recent quarter (Q4 2025) totaled -$3.03 million USD.
- The company's FY2026 adjusted EBITDA outlook includes an investment of approximately $60 million in new initiatives such as Hypercon and Surf Bio, indicating a focus on expanding business operations and revenue base.
Peer Outperformance in Biotechnology
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 6 | 16.2% | 43.2% | 90.1% | CAH 392% · MCK 346% · COR 168% |
| Managed Health Care | 8 | 40.4% | -5.3% | 2.3% | OSCR 84% · HQY 56% · ELV 17% |
| Health Care Services | 20 | 21.1% | 37.6% | -0.3% | HIMS 239% · RDNT 173% · DGX 76% |
| Health Care Facilities | 24 | 6.0% | 6.5% | -4.5% | NHC 271% · THC 261% · ENSG 129% |
| Health Care Equipment | 50 | -2.7% | -0.2% | -21.1% | POCI 11050% · UFPT 341% · GKOS 222% |
| Pharmaceuticals | 62 | -10.5% | 14.8% | -38.6% | LQDA 2472% · INDV 1099% · ETON 1051% |
| Health Care Supplies | 12 | 14.1% | -8.9% | -39.7% | LNTH 287% · HAE 54% · MMSI 20% |
| Life Sciences Tools & Services | 109 | 4.3% | -11.3% | -68.4% | SNWV 1757% · MEDP 231% · NTRA 199% |
| Health Care Technology | 21 | -25.8% | -52.6% | -79.2% | SPOK 68% · HSTM 3% · VEEV -13% |
| Biotechnology ← | 364 | 0.6% | -21.7% | -79.4% | CELZ 1280% · DNTH 1221% · ELVN 1069% |
Latest Trefis Analyses
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 146.69 |
| Mkt Cap | 37.7 |
| Rev LTM | 13,288 |
| Op Inc LTM | 2,137 |
| FCF LTM | 1,514 |
| FCF 3Y Avg | 1,629 |
| CFO LTM | 2,040 |
| CFO 3Y Avg | 2,092 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 11.4% |
| Rev Chg 3Y Avg | 6.2% |
| Rev Chg Q | 7.8% |
| QoQ Delta Rev Chg LTM | 1.9% |
| Op Inc Chg LTM | 21.2% |
| Op Inc Chg 3Y Avg | 10.9% |
| Op Mgn LTM | 24.2% |
| Op Mgn 3Y Avg | 22.8% |
| QoQ Delta Op Mgn LTM | -0.3% |
| CFO/Rev LTM | 23.2% |
| CFO/Rev 3Y Avg | 24.4% |
| FCF/Rev LTM | 19.1% |
| FCF/Rev 3Y Avg | 17.7% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 37.7 |
| P/S | 4.9 |
| P/Op Inc | 14.5 |
| P/EBIT | 22.3 |
| P/E | 40.9 |
| P/CFO | 15.7 |
| Total Yield | 4.1% |
| Dividend Yield | 1.3% |
| FCF Yield 3Y Avg | 6.0% |
| D/E | 0.3 |
| Net D/E | 0.2 |
Clinical Pipeline
| Drug Candidate | Indication | Phase 3 Trials | Est. Primary Completion |
|---|---|---|---|
| XYOSTED (testosterone enanthate) | Male hypogonadism | 1 | Mar 2028 |
Price Behavior
| Market Price | $112.45 | |
| Market Cap ($ Bil) | 13.2 | |
| First Trading Date | 03/16/2004 | |
| Distance from 52W High | 0.0% | |
| 50 Days | 200 Days | |
| DMA Price | $96.00 | $75.62 |
| DMA Trend | up | up |
| Distance from DMA | 17.1% | 48.7% |
| 3M | 1YR | |
| Volatility | 47.7% | 37.3% |
| Downside Capture | -110.82 | 21.33 |
| Upside Capture | 164.28 | 60.81 |
| Correlation (SPY) | 7.6% | 19.8% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.02 | 0.17 | 0.30 | 0.61 | 0.56 | 0.68 |
| Up Beta | 0.10 | 0.11 | 0.54 | 0.96 | 1.14 | 0.63 |
| Down Beta | -0.92 | -0.81 | 0.10 | 0.64 | 0.32 | 0.83 |
| Up Capture | 341% | 165% | 142% | 83% | 51% | 46% |
| Bmk +ve Days | 10 | 21 | 32 | 68 | 138 | 427 |
| Stock +ve Days | 11 | 22 | 35 | 67 | 127 | 399 |
| Down Capture | -147% | -134% | -111% | -3% | 29% | 76% |
| Bmk -ve Days | 11 | 21 | 32 | 59 | 113 | 324 |
| Stock -ve Days | 9 | 19 | 28 | 59 | 123 | 347 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with HALO | |
|---|---|---|---|---|
| HALO | 48.6% | 37.1% | 1.13 | - |
| Sector ETF (XLV) | 24.4% | 16.1% | 1.16 | 42.0% |
| Equity (SPY) | 16.9% | 12.9% | 0.94 | 19.6% |
| Gold (GLD) | 19.1% | 29.3% | 0.60 | 15.9% |
| Commodities (DBC) | 46.3% | 20.6% | 1.73 | -9.4% |
| Real Estate (VNQ) | 4.9% | 13.6% | 0.10 | 20.5% |
| Bitcoin (BTCUSD) | -30.6% | 44.3% | -0.70 | 12.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with HALO | |
|---|---|---|---|---|
| HALO | 22.1% | 40.4% | 0.60 | - |
| Sector ETF (XLV) | 6.4% | 15.2% | 0.24 | 41.6% |
| Equity (SPY) | 12.9% | 17.2% | 0.57 | 31.9% |
| Gold (GLD) | 19.1% | 18.8% | 0.83 | 5.8% |
| Commodities (DBC) | 11.2% | 19.5% | 0.45 | 0.4% |
| Real Estate (VNQ) | 1.1% | 18.8% | -0.05 | 31.3% |
| Bitcoin (BTCUSD) | 12.5% | 52.5% | 0.42 | 12.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with HALO | |
|---|---|---|---|---|
| HALO | 26.4% | 42.7% | 0.69 | - |
| Sector ETF (XLV) | 10.6% | 16.7% | 0.51 | 42.3% |
| Equity (SPY) | 15.1% | 18.0% | 0.72 | 37.3% |
| Gold (GLD) | 12.1% | 16.4% | 0.61 | 5.4% |
| Commodities (DBC) | 8.3% | 18.1% | 0.37 | 9.1% |
| Real Estate (VNQ) | 4.4% | 20.7% | 0.18 | 28.1% |
| Bitcoin (BTCUSD) | 62.6% | 66.2% | 1.02 | 7.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 9/9/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/6/2026 | 20.2% | 17.4% | 28.5% |
| 5/11/2026 | 6.8% | 1.6% | 6.2% |
| 2/17/2026 | -9.0% | -12.6% | -20.9% |
| 11/3/2025 | 2.8% | 2.7% | -4.9% |
| 8/5/2025 | 2.5% | 5.3% | 20.7% |
| 5/6/2025 | 18.1% | -15.4% | -9.8% |
| 2/18/2025 | -0.2% | 0.2% | 11.1% |
| 10/31/2024 | 13.0% | 18.0% | -3.9% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 19 | 18 | 14 |
| # Negative | 4 | 5 | 9 |
| Median Positive | 6.6% | 7.1% | 16.1% |
| Median Negative | -4.5% | -8.0% | -9.8% |
| Max Positive | 20.2% | 31.6% | 43.2% |
| Max Negative | -9.0% | -15.4% | -33.8% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/6/2026 | 20.2% | 17.4% | 28.5% |
| 5/11/2026 | 6.8% | 1.6% | 6.2% |
| 2/17/2026 | -9.0% | -12.6% | -20.9% |
| 11/3/2025 | 2.8% | 2.7% | -4.9% |
| 8/5/2025 | 2.5% | 5.3% | 20.7% |
| 5/6/2025 | 18.1% | -15.4% | -9.8% |
| 2/18/2025 | -0.2% | 0.2% | 11.1% |
| 10/31/2024 | 13.0% | 18.0% | -3.9% |
| 8/6/2024 | 4.2% | 7.8% | 17.5% |
| 5/7/2024 | 1.9% | 6.3% | 24.8% |
| 2/20/2024 | 6.6% | 10.7% | 12.2% |
| 11/6/2023 | 10.0% | 6.4% | 13.4% |
| 8/8/2023 | -1.6% | 1.6% | -9.6% |
| 5/9/2023 | 12.8% | 8.9% | 11.7% |
| 2/21/2023 | 0.8% | -3.4% | -33.8% |
| 11/8/2022 | 8.5% | 17.9% | 26.2% |
| 8/9/2022 | 1.8% | 2.7% | -8.4% |
| 5/10/2022 | 1.0% | 16.4% | 17.7% |
| 2/22/2022 | 2.9% | 8.7% | 14.6% |
| 8/9/2021 | 2.0% | 2.1% | 4.0% |
| 5/10/2021 | -7.4% | -8.0% | -14.6% |
| 2/23/2021 | 9.0% | -4.7% | -12.1% |
| 11/2/2020 | 11.3% | 31.6% | 43.2% |
| SUMMARY STATS | |||
| # Positive | 19 | 18 | 14 |
| # Negative | 4 | 5 | 9 |
| Median Positive | 6.6% | 7.1% | 16.1% |
| Median Negative | -4.5% | -8.0% | -9.8% |
| Max Positive | 20.2% | 31.6% | 43.2% |
| Max Negative | -9.0% | -15.4% | -33.8% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/06/2026 | 10-Q |
| 03/31/2026 | 05/11/2026 | 10-Q |
| 12/31/2025 | 02/17/2026 | 10-K |
| 09/30/2025 | 11/03/2025 | 10-Q |
| 06/30/2025 | 08/05/2025 | 10-Q |
| 03/31/2025 | 05/06/2025 | 10-Q |
| 12/31/2024 | 02/18/2025 | 10-K |
| 09/30/2024 | 10/31/2024 | 10-Q |
| 06/30/2024 | 08/06/2024 | 10-Q |
| 03/31/2024 | 05/07/2024 | 10-Q |
| 12/31/2023 | 02/20/2024 | 10-K |
| 09/30/2023 | 11/06/2023 | 10-Q |
| 06/30/2023 | 08/08/2023 | 10-Q |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 02/21/2023 | 10-K |
| 09/30/2022 | 11/08/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/06/2026 | 10-Q |
| 03/31/2026 | 05/11/2026 | 10-Q |
| 12/31/2025 | 02/17/2026 | 10-K |
| 09/30/2025 | 11/03/2025 | 10-Q |
| 06/30/2025 | 08/05/2025 | 10-Q |
| 03/31/2025 | 05/06/2025 | 10-Q |
| 12/31/2024 | 02/18/2025 | 10-K |
| 09/30/2024 | 10/31/2024 | 10-Q |
| 06/30/2024 | 08/06/2024 | 10-Q |
| 03/31/2024 | 05/07/2024 | 10-Q |
| 12/31/2023 | 02/20/2024 | 10-K |
| 09/30/2023 | 11/06/2023 | 10-Q |
| 06/30/2023 | 08/08/2023 | 10-Q |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 02/21/2023 | 10-K |
| 09/30/2022 | 11/08/2022 | 10-Q |
| 06/30/2022 | 08/09/2022 | 10-Q |
| 03/31/2022 | 05/10/2022 | 10-Q |
| 12/31/2021 | 02/22/2022 | 10-K |
| 09/30/2021 | 11/02/2021 | 10-Q |
| 06/30/2021 | 08/09/2021 | 10-Q |
| 03/31/2021 | 05/10/2021 | 10-Q |
| 12/31/2020 | 02/23/2021 | 10-K |
| 09/30/2020 | 11/02/2020 | 10-Q |
| 06/30/2020 | 08/10/2020 | 10-Q |
| 03/31/2020 | 05/11/2020 | 10-Q |
| 12/31/2019 | 02/24/2020 | 10-K |
| 09/30/2019 | 11/12/2019 | 10-Q |
Recent Forward Guidance
Updated 8/7/2026Latest: Q2 2026 Earnings Reported 8/6/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Total Revenue | Reported | 1.83 Bil | 1.87 Bil | 1.91 Bil | 6.4% | Raised | Guidance: 1.76 Bil for 2026 | |
| 2026 Royalty Revenue | Reported | 1.22 Bil | 1.23 Bil | 1.25 Bil | 7.2% | Raised | Guidance: 1.15 Bil for 2026 | |
| 2026 Adjusted EBITDA | Reported | 1.23 Bil | 1.25 Bil | 1.28 Bil | 7.5% | Raised | Guidance: 1.17 Bil for 2026 | |
| 2026 Non-GAAP Diluted EPS | Reported | 8.65 | 8.82 | 9 | 10.3% | Raised | Guidance: 8 for 2026 | |
Prior: Q1 2026 Earnings Reported 5/11/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Total Revenue | Reported | 1.71 Bil | 1.76 Bil | 1.81 Bil | 0 | Affirmed | Guidance: 1.76 Bil for 2026 | |
| 2026 Royalty Revenue | Reported | 1.13 Bil | 1.15 Bil | 1.17 Bil | 0 | Affirmed | Guidance: 1.15 Bil for 2026 | |
| 2026 Adjusted EBITDA | Reported | 1.12 Bil | 1.17 Bil | 1.21 Bil | 0 | Affirmed | Guidance: 1.17 Bil for 2026 | |
| 2026 Non-GAAP Diluted EPS | Reported | 7.75 | 8 | 8.25 | 0 | Affirmed | Guidance: 8 for 2026 | |
| 2026 Share Repurchases | Reported | 400.00 Mil | ||||||
Q4 2025 Earnings Reported 2/17/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Total Revenue | Reported | 1.71 Bil | 1.76 Bil | 1.81 Bil | 31.6% | Higher New | Actual: 1.34 Bil for 2025 | |
| 2026 Royalty Revenue | Reported | 1.13 Bil | 1.15 Bil | 1.17 Bil | 32.9% | Higher New | Actual: 865.00 Mil for 2025 | |
| 2026 Total Revenue Growth | Reported | 22.0% | 26.0% | 30.0% | ||||
| 2026 Royalty Revenue Growth | Reported | 30.0% | 32.5% | 35.0% | ||||
| 2026 Adjusted EBITDA | Reported | 1.12 Bil | 1.17 Bil | 1.21 Bil | 28.0% | Higher New | Actual: 910.00 Mil for 2025 | |
| 2026 Adjusted EBITDA Growth | Reported | 71.0% | 77.0% | 83.0% | ||||
| 2026 Non-GAAP Diluted EPS | Reported | 7.75 | 8 | 8.25 | 27.0% | Higher New | Actual: 6.3 for 2025 | |
| 2026 Non-GAAP Diluted EPS Growth | Reported | 87.0% | 93.0% | 99.0% | ||||
Q3 2025 Earnings Reported 11/3/2025
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2025 Total Revenue | Reported | 1.30 Bil | 1.34 Bil | 1.38 Bil | 1.7% | Raised | Guidance: 1.31 Bil for 2025 | |
| 2025 Royalty Revenue | Reported | 850.00 Mil | 865.00 Mil | 880.00 Mil | 2.7% | Raised | Guidance: 842.50 Mil for 2025 | |
| 2025 Adjusted EBITDA | Reported | 885.00 Mil | 910.00 Mil | 935.00 Mil | 2.2% | Raised | Guidance: 890.00 Mil for 2025 | |
| 2025 Non-GAAP Diluted EPS | Reported | 6.1 | 6.3 | 6.5 | 1.6% | Raised | Guidance: 6.2 for 2025 | |
Insider Activity
Updated 9/17/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Posard, Matthew L | Direct | Sell | 9172026 | 107.74 | 18,996 | 2,046,581 | 6,339,165 | Form | |
| 2 | Torley, Helen | PRESIDENT AND CEO | Direct | Sell | 9112026 | 107.24 | 20,000 | 2,144,856 | 82,338,883 | Form |
| 3 | Torley, Helen | PRESIDENT AND CEO | Direct | Sell | 9112026 | 107.17 | 20,000 | 2,143,319 | 82,279,890 | Form |
| 4 | Torley, Helen | PRESIDENT AND CEO | Direct | Sell | 9112026 | 107.43 | 20,000 | 2,148,536 | 82,480,141 | Form |
| 5 | Torley, Helen | PRESIDENT AND CEO | Direct | Sell | 8192026 | 107.00 | 20,000 | 2,139,976 | 82,151,539 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Posard, Matthew L | Direct | Sell | 9172026 | 107.74 | 18,996 | 2,046,581 | 6,339,165 | Form | |
| 2 | Torley, Helen | PRESIDENT AND CEO | Direct | Sell | 9112026 | 107.24 | 20,000 | 2,144,856 | 82,338,883 | Form |
| 3 | Torley, Helen | PRESIDENT AND CEO | Direct | Sell | 9112026 | 107.17 | 20,000 | 2,143,319 | 82,279,890 | Form |
| 4 | Torley, Helen | PRESIDENT AND CEO | Direct | Sell | 9112026 | 107.43 | 20,000 | 2,148,536 | 82,480,141 | Form |
| 5 | Torley, Helen | PRESIDENT AND CEO | Direct | Sell | 8192026 | 107.00 | 20,000 | 2,139,976 | 82,151,539 | Form |
| 6 | Torley, Helen | PRESIDENT AND CEO | Direct | Sell | 8192026 | 104.18 | 20,000 | 2,083,525 | 79,984,427 | Form |
| 7 | Torley, Helen | PRESIDENT AND CEO | Direct | Sell | 8192026 | 102.60 | 20,000 | 2,052,091 | 78,777,733 | Form |
| 8 | Connaughton, Bernadette | Direct | Sell | 8112026 | 102.80 | 1,626 | 167,153 | 4,154,970 | Form | |
| 9 | Torley, Helen | PRESIDENT AND CEO | Direct | Sell | 7092026 | 79.77 | 1,923 | 153,391 | 61,242,985 | Form |
| 10 | Connaughton, Bernadette | Direct | Sell | 7022026 | 76.71 | 1,625 | 124,651 | 3,225,114 | Form | |
| 11 | Krishnan, Mahesh | Direct | Sell | 6302026 | 75.00 | 7,304 | 547,800 | 1,084,650 | Form | |
| 12 | Torley, Helen | PRESIDENT AND CEO | Direct | Sell | 6032026 | 69.07 | 10,000 | 690,653 | 53,026,948 | Form |
| 13 | Torley, Helen | PRESIDENT AND CEO | Direct | Sell | 6032026 | 66.39 | 20,000 | 1,327,745 | 50,970,818 | Form |
| 14 | Torley, Helen | PRESIDENT AND CEO | Direct | Sell | 6032026 | 67.58 | 20,000 | 1,351,610 | 51,886,953 | Form |
| 15 | Connaughton, Bernadette | Direct | Sell | 6022026 | 66.21 | 1,625 | 107,591 | 2,891,324 | Form | |
| 16 | Torley, Helen | PRESIDENT AND CEO | Direct | Sell | 5132026 | 69.19 | 10,000 | 691,908 | 53,123,316 | Form |
| 17 | Torley, Helen | PRESIDENT AND CEO | Direct | Sell | 5132026 | 71.75 | 20,000 | 1,435,027 | 55,089,250 | Form |
| 18 | Torley, Helen | PRESIDENT AND CEO | Direct | Sell | 5132026 | 65.35 | 20,000 | 1,306,940 | 50,172,109 | Form |
| 19 | Connaughton, Bernadette | Direct | Sell | 5052026 | 63.48 | 1,625 | 103,155 | 2,443,853 | Form | |
| 20 | Torley, Helen | PRESIDENT AND CEO | Direct | Sell | 4072026 | 63.50 | 10,000 | 634,982 | 48,752,617 | Form |
| 21 | Torley, Helen | PRESIDENT AND CEO | Direct | Sell | 4022026 | 64.24 | 20,000 | 1,284,721 | 49,319,147 | Form |
| 22 | Torley, Helen | PRESIDENT AND CEO | Direct | Sell | 4022026 | 65.38 | 20,000 | 1,307,516 | 50,194,232 | Form |
| 23 | Caudill, Cortney | SVP, CHIEF OPERATING OFFICER | Direct | Sell | 3102026 | 67.64 | 8,857 | 599,087 | 477,200 | Form |
| 24 | Caudill, Cortney | SVP, CHIEF OPERATING OFFICER | Direct | Sell | 3102026 | 67.80 | 20,000 | 1,356,072 | 974,067 | Form |
| 25 | Torley, Helen | PRESIDENT AND CEO | Direct | Sell | 3042026 | 70.21 | 10,000 | 702,114 | 53,906,883 | Form |
| 26 | Torley, Helen | PRESIDENT AND CEO | Direct | Sell | 3042026 | 69.01 | 20,000 | 1,380,149 | 52,982,528 | Form |
| 27 | Torley, Helen | PRESIDENT AND CEO | Direct | Sell | 3042026 | 69.69 | 20,000 | 1,393,894 | 53,510,214 | Form |
| 28 | Torley, Helen | PRESIDENT AND CEO | Direct | Sell | 2052026 | 78.64 | 10,000 | 786,366 | 55,731,222 | Form |
| 29 | Torley, Helen | PRESIDENT AND CEO | Direct | Sell | 2052026 | 77.24 | 20,000 | 1,544,820 | 54,742,178 | Form |
| 30 | Torley, Helen | PRESIDENT AND CEO | Direct | Sell | 2052026 | 76.12 | 20,000 | 1,522,317 | 53,944,759 | Form |
| 31 | Connaughton, Bernadette | Direct | Sell | 1062026 | 70.25 | 2,000 | 140,500 | 2,818,641 | Form | |
| 32 | Caudill, Cortney | SVP, CHIEF OPERATING OFFICER | Direct | Sell | 12192025 | 65.19 | 4,263 | 277,905 | 830,325 | Form |
| 33 | Connaughton, Bernadette | Direct | Sell | 12012025 | 71.60 | 829 | 59,356 | 3,016,007 | Form | |
| 34 | Torley, Helen | PRESIDENT AND CEO | Direct | Sell | 12012025 | 68.92 | 16,569 | 1,141,925 | 48,844,455 | Form |
| 35 | Torley, Helen | PRESIDENT AND CEO | Direct | Sell | 11122025 | 70.55 | 20,000 | 1,410,990 | 51,763,526 | Form |
| 36 | Torley, Helen | PRESIDENT AND CEO | Direct | Sell | 11122025 | 69.13 | 20,000 | 1,382,600 | 50,722,013 | Form |
| 37 | Torley, Helen | PRESIDENT AND CEO | Direct | Sell | 11122025 | 68.72 | 20,000 | 1,374,339 | 50,418,917 | Form |
| 38 | Connaughton, Bernadette | Direct | Sell | 11122025 | 68.48 | 2,000 | 136,960 | 2,941,353 | Form | |
| 39 | Torley, Helen | PRESIDENT AND CEO | Direct | Sell | 10032025 | 69.03 | 20,000 | 1,380,638 | 50,650,022 | Form |
| 40 | Torley, Helen | PRESIDENT AND CEO | Direct | Sell | 10032025 | 71.20 | 20,000 | 1,424,083 | 52,243,827 | Form |
| 41 | Torley, Helen | PRESIDENT AND CEO | Direct | Sell | 10032025 | 75.35 | 20,000 | 1,507,024 | 55,286,617 | Form |
| 42 | Connaughton, Bernadette | Direct | Sell | 10012025 | 75.24 | 2,000 | 150,481 | 3,382,211 | Form | |
| 43 | Labrosse, Nicole | SVP, CHIEF FINANCIAL OFFICER | Direct | Sell | 9232025 | 77.95 | 2,227 | 173,584 | 1,720,957 | Form |
| 44 | Labrosse, Nicole | SVP, CHIEF FINANCIAL OFFICER | Direct | Sell | 9112025 | 75.71 | 20,000 | 1,514,267 | 1,840,289 | Form |
| 45 | Torley, Helen | PRESIDENT AND CEO | Direct | Sell | 9042025 | 74.04 | 20,000 | 1,480,772 | 54,323,535 | Form |
| 46 | Torley, Helen | PRESIDENT AND CEO | Direct | Sell | 9042025 | 74.44 | 20,000 | 1,488,726 | 54,615,328 | Form |
| 47 | Torley, Helen | PRESIDENT AND CEO | Direct | Sell | 9042025 | 73.76 | 20,000 | 1,475,128 | 54,116,475 | Form |
| 48 | Connaughton, Bernadette | Direct | Sell | 9022025 | 73.68 | 4,000 | 294,736 | 3,459,614 | Form |
Investor Activity (13F)
Updated Sep 21, 2026Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.